Latest Healthcare News

Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.

Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.

EVE Health Group has reported a 19% decline in revenue and a 17% increase in net loss for the financial year ended June 2025, highlighting ongoing challenges in its health and wellness segments.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Hydrix Limited narrowed its FY2025 loss to $2.92 million, driven by significant cost reductions and steady revenue from expanding international medtech clients. Despite ongoing challenges in sales cycles and funding, the company remains focused on innovation and strategic investments.

Optiscan Imaging Limited reported a 17.6% revenue decline and a 4.1% increase in net loss for FY25, driven by lower orders and higher R&D spending. The company unveiled two new medical imaging devices as it ramps up commercial efforts.

Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.

Rhythm Biosciences has significantly reduced its annual loss by 44%, boosted by a 91% rise in other income, while launching a new wholly owned subsidiary, RHY GeneType Pty Ltd.

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.